2018 (v1)
Publication
No description
Uploaded on: March 27, 2023
-
-
2018 (v1)Publication
No description
Uploaded on: March 27, 2023 -
2018 (v1)Publication
Background Approximately two-thirds of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) need long-term intravenous immunoglobulin. Subcutaneous immunoglobulin (SCIg) is an alternative option for immunoglobulin delivery, but has not previously been investigated in a large trial of CIDP. The PATH study compared relapse rates...
Uploaded on: April 14, 2023 -
2019 (v1)Publication
In patients with chronic inflammatory demyelinating polyneuropathy (CIDP), intravenous immunoglobulin (IVIG) is recommended to be periodically reduced to assess the need for ongoing therapy. However, little is known about the effectiveness of restabilization with IVIG in patients who worsen after IVIG withdrawal. In the Polyneuropathy And...
Uploaded on: April 14, 2023 -
2019 (v1)Publication
No description
Uploaded on: February 23, 2024 -
2019 (v1)Publication
Intravenous immunoglobulin (IVIG) is a potential therapy for chronic inflammatory demyelinating polyneuropathy (CIDP). To investigate the efficacy and safety of the IVIG IgPro10 (Privigen) for treatment of CIDP, results from Privigen Impact on Mobility and Autonomy (PRIMA), a prospective, open-label, single-arm study of IVIG in immunoglobulin...
Uploaded on: March 27, 2023